Company intelligence / Profile preview

BioVascular

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

BioVascular began human clinical trials of saratin for hemodialysis graft access in late 2006 and planned trials for peripheral artery grafts in early 2007. A second product targeting cardiovascular risk factors was planned to enter human studies in mid 2007.

Therapeutic areas: NephrologyCardiovascular
Modalities: Recombinant proteinSmall moleculeDevice
Industry: Biotech

Partnerships

Merck KGaA

Beyond the preview

Go deeper on BioVascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioVascular.

Explore the full profile